(Q44827836)

6 December 2017

title

Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis (English)

1 reference

6 December 2017

0 references

1 reference

2

Daniel C Javitt

1 reference

6 December 2017

Uriel Heresco-Levy

1

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

6 December 2017

published in

Schizophrenia Research

1 reference

6 December 2017

volume

66

1 reference

6 December 2017

issue

2-3

1 reference

6 December 2017

page(s)

89-96

1 reference

Dose-finding trial of D-cycloserine added to neuroleptics for negative symptoms in schizophrenia

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

D-cycloserine added to clozapine for patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Recent advances in the phencyclidine model of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Amelioration of negative symptoms in schizophrenia by glycine.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

A.E. Bennett Research Award. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Adjunctive high-dose glycine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Glycine potentiates the NMDA response in cultured mouse brain neurons

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Glycine and D-serine decrease MK-801-induced hyperactivity in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

D-cycloserine adjuvant therapy to molindone in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

D-serine added to antipsychotics for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

Efficacy and tolerance of D-cycloserine in drug-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0920-9964%2803%2900129-4

7 January 2021

10.1016/S0920-9964(03)00129-4

Identifiers

DOI

1 reference

6 December 2017

1 reference